Literature DB >> 15654605

18F-FDG-avid sites mimicking active disease in pediatric Hodgkin's.

Sue C Kaste1, Scott C Howard, Elizabeth B McCarville, Matthew J Krasin, Philip G Kogos, Melissa M Hudson.   

Abstract

About 1,700 children in the United States are diagnosed yearly with lymphomas; Hodgkin's disease accounts for approximately half of these cases, or 6% of all childhood cancers. Contemporary therapy allows for the achievement of remission in the majority of cases. The fusion of positron emission tomography (PET) with CT provides the most accurate imaging method for disease characterization and treatment response. However, experience with 18F-FDG PET-CT is limited in pediatric Hodgkin's disease. Numerous non-oncologic processes can mimic recurrent or residual tumor. This pictorial addresses mimickers of disease such as uptake in normal structures, infections, transforming germinal canters and effects of therapy on normal tissues. It is essential for radiologists to be familiar with these findings in order to stage disease activity and therapeutic response accurately.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15654605     DOI: 10.1007/s00247-004-1340-3

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  18 in total

1.  Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment.

Authors:  Gerhard W Goerres; Gustav K Von Schulthess; Thomas F Hany
Journal:  AJR Am J Roentgenol       Date:  2002-11       Impact factor: 3.959

2.  Pediatric Hodgkin's therapy: time for a paradigm shift.

Authors:  Melissa M Hudson
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

3.  Progressive transformation of germinal centers with and without association to Hodgkin's disease.

Authors:  M L Hansmann; C Fellbaum; P K Hui; P Moubayed
Journal:  Am J Clin Pathol       Date:  1990-02       Impact factor: 2.493

Review 4.  Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions.

Authors:  L M Hollingshead; K L Goa
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

5.  Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.

Authors:  Y Sugawara; S J Fisher; K R Zasadny; P V Kison; L H Baker; R L Wahl
Journal:  J Clin Oncol       Date:  1998-01       Impact factor: 44.544

Review 6.  Clinical role of FDG PET in evaluation of cancer patients.

Authors:  Lale Kostakoglu; Harry Agress; Stanley J Goldsmith
Journal:  Radiographics       Date:  2003 Mar-Apr       Impact factor: 5.333

7.  Uptake rates of 18F-fluorodeoxyglucose and 11C-choline in lung cancer and pulmonary tuberculosis: a positron emission tomography study.

Authors:  Toshihiko Hara; Noboru Kosaka; Tsuneo Suzuki; Koichiro Kudo; Hitoshi Niino
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

8.  Use of Tl-201 to detect untreated pediatric Hodgkin disease.

Authors:  B D Fletcher; W M Kauffman; S C Kaste; H T Winer-Muram; L Fang; G Chen; M Hudson
Journal:  Radiology       Date:  1995-09       Impact factor: 11.105

9.  Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.

Authors:  Henry W D Yeung; Ravinder K Grewal; Mithat Gonen; Heiko Schöder; Steven M Larson
Journal:  J Nucl Med       Date:  2003-11       Impact factor: 10.057

10.  Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT.

Authors:  Hedva Lerman; Ur Metser; Dan Grisaru; Ami Fishman; Gennady Lievshitz; Einat Even-Sapir
Journal:  J Nucl Med       Date:  2004-02       Impact factor: 10.057

View more
  9 in total

1.  F-18 FDG-PET imaging and correlation with CT in staging and follow-up of pediatric lymphomas.

Authors:  Miguel Hernandez-Pampaloni; Amol Takalkar; Jian Q Yu; Hongming Zhuang; Abass Alavi
Journal:  Pediatr Radiol       Date:  2006-04-19

2.  Is PET/CT necessary in paediatric oncology? For.

Authors:  Christiane Franzius; Kai Uwe Juergens; Otmar Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08       Impact factor: 9.236

Review 3.  PET/CT in paediatric oncology: indications and pitfalls.

Authors:  Christiane Franzius; Kai Uwe Juergens
Journal:  Pediatr Radiol       Date:  2009-06

4.  PET imaging in pediatric neuroradiology: current and future applications.

Authors:  Sunhee Kim; Noriko Salamon; Hollie A Jackson; Stefan Blüml; Ashok Panigrahy
Journal:  Pediatr Radiol       Date:  2009-11-24

5.  Time-dependent changes in 18F-FDG activity in the thymus and bone marrow following combination chemotherapy in paediatric patients with lymphoma.

Authors:  Ingeborg Goethals; Pieter Hoste; Ciel De Vriendt; Peter Smeets; Joris Verlooy; Hamphrey Ham
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-10       Impact factor: 9.236

6.  The incremental value of 18F-FDG PET/CT in paediatric malignancies.

Authors:  Zvi Bar-Sever; Zohar Keidar; Ayelet Ben-Barak; Rachel Bar-Shalom; Sergey Postovsky; Luda Guralnik; Myriam W Ben Arush; Ora Israel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-10-18       Impact factor: 9.236

7.  Guidelines for 18F-FDG PET and PET-CT imaging in paediatric oncology.

Authors:  J Stauss; C Franzius; T Pfluger; K U Juergens; L Biassoni; J Begent; R Kluge; H Amthauer; T Voelker; L Højgaard; S Barrington; S Hain; T Lynch; K Hahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08       Impact factor: 9.236

Review 8.  The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood.

Authors:  Chrissa Sioka
Journal:  Eur J Pediatr       Date:  2013-04-05       Impact factor: 3.183

9.  Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT.

Authors:  Linda Jorgov; Françoise Montravers; Sona Balogova; Christine Ragu; Hélène Pacquement; Thierry Leblanc; Samuel Abbou; Hubert Ducou-Lepointe; Judith Landman-Parker; Jean-Noёl Talbot
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-14       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.